Novan Announces Presentation of Anti-Viral Data at International Papillomavirus Conference
March 01, 2017 09:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., March 01, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that preclinical data demonstrating the anti-viral effects of the Company’s...
Novan Announces Statistically Significant Phase 2 Clinical Trial Results for SB206
November 29, 2016 06:05 ET
|
Novan, Inc.
Number of Patients with Complete Clearance of Genital Warts Provides Clinical Evidence of Nitric Oxide Anti-Viral Activity Against HPV Company Plans End-of-Phase 2 Meeting for First Half of...
Genticel to Present Clinical Results of GTL001 and Preclinical Results of GTL002 at EUROGIN 2016 Congress in Salzburg, Austria
June 15, 2016 16:01 ET
|
Genticel S.A.
PARIS and TOULOUSE, France, June 15, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
Genticel Reports Initial Results at 12 Months From Phase 2 Trial of HPV Immunotherapeutic Candidate, GTL001
January 27, 2016 13:22 ET
|
Genticel S.A.
12- month primary endpoint not met in the overall populationStatistical difference in viral clearance rates in 2 predefined key subgroups DSMB recommends continuation of the study per protocol18-month...
Officials Cover Up Dangers of HPV Vaccine Declares Scientist
January 18, 2016 12:23 ET
|
Weston A. Price Foundation
Washington, D.C., Jan. 18, 2016 (GLOBE NEWSWIRE) -- Dr. Sin Hang Lee, MD, Director, Milford Molecular Diagnostics Laboratory, has submitted an official, open-letter complaint to the Director-General...
Genticel to Evaluate Roche Molecular Systems’ cobas® HPV Test in Preparation for Phase 3 Program of GTL001
January 07, 2016 08:00 ET
|
Genticel S.A.
PARIS and TOULOUSE, France, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
(UPDATED) UNITY Consortium Established to Support Immunizations for Today's Teens and Young Adults
August 28, 2015 14:04 ET
|
UNITY Consortium
NEWTOWN, Pa., Aug. 28, 2015 (GLOBE NEWSWIRE) -- UNITY Consortium has launched as a coalition that brings together a wide range of organizations with a singular focus on improving adolescent and young...
Hemispherx and GP Pharm Agree to Establish a Manufacturing Operation in Argentina to Serve Latin America Markets and Ancillary Markets
May 21, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, May 21, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced the preliminary stage agreement required to manufacture...
Provista Diagnostics Licenses Biomarker Technologies Developed at Arizona State University
October 25, 2013 05:00 ET
|
Provista Diagnostics, Inc.
Scottsdale, Arizona, Oct. 25, 2013 (GLOBE NEWSWIRE) -- Provista Diagnostics, Inc., a leading molecular diagnostics
company focused on developing and commercializing proprietary
diagnostic, prognostic...
Hemispherx Biopharma Announces Financial Results for the Three Months Ended June 30, 2013
August 09, 2013 16:23 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 9, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced its financial results for the three months ended June 30, 2013. The net loss (including non-cash effects) was...